Abstract: The present invention discloses a one-way limiting expandable artificial heart valve which comprises a valve seat (1), a valve leaflet stent (2) and three valve leaflets (3) wherein the valve seat (1) comprises a one-way limiting expandable annular metal seat (4), the annular metal seat (4) is composed of three sections of seat body units (5), the head end of each section of seat body unit (5) is sequentially provided with a first rivet (8), a limiting protrusion (7) and a first long circular groove (6), the tail end of each section of seat body unit (5) is sequentially provided with a second long circular groove (9), a second limiting hole (11) and a first limiting hole (10), and a second rivet (12), and the artificial heart valve has a normal use original state and a one-way limiting expansion state.

Abstract: A split type precisely-anchorable transcatheter aortic valve system comprises a split transcatheter aortic valve anchoring stent (10) and a transcatheter artificial biological aortic valve (20), wherein the shape and structure of the transcatheter aortic valve anchoring stent (10) are matched with the real structure of the aortic valve after the patient's image data is subjected to three-dimensional reconstruction, the transcatheter aortic valve anchoring stent (10) is delivered to the aortic valve position of the patient to be released, deformed and combined with the aortic valve leaflet tissue and the subvalvular tissue of the patient; the transcatheter artificial biological aortic valve (20) is delivered into the transcatheter aortic valve anchoring stent (10) to be released, the valve stent is deformed to expand the valve to the functional state, the transcatheter aortic valve anchoring stent (10) is deformed again and combined with the expanded transcatheter artificial biological aortic valve (20), and m

Abstract: A split type precisely-anchorable transcatheter mitral valve system comprises a split transcatheter mitral valve anchoring stent (10) and a transcatheter artificial biological mitral valve (20), wherein the shape and structure of the transcatheter mitral valve anchoring stent (10) are matched with the mitral valve real structure after the patient image data is subjected to three-dimensional reconstruction, the transcatheter mitral valve anchoring stent (10) is firstly delivered to the mitral valve position of the patient to be released and deformed, and the transcatheter artificial biological mitral valve (20) is in personalized precise alignment and coaptation with tissues on the mitral valve position of the patient and under the petals; the transcatheter artificial biological mitral valve (20) is delivered into the transcatheter mitral valve anchoring stent (10) to be released, the transcatheter artificial biological mitral valve (20) is released and deformed and expanded to a functional state, the transcat

Abstract: A split type precisely-anchorable transcatheter valve-in-ring system comprises a split transcatheter valve-in-ring anchoring stent (10) and a transcatheter artificial biological valve-in-ring (20), wherein the shape and structure of the transcatheter valve-in-ring anchoring stent (10) are matched with the real structure of the annuloplasty ring and supravalvular and infravalvular tissues after three-dimensional reconstruction based on imaging data of a patient who have undergone valve failure after implantation of a annuloplasty ring (30), the transcatheter valve-in-ring anchoring stent (10) is firstly delivered to the patient's failed annuloplasty ring for release, deformation and alignment with the supravalvular and infravalvular tissues of the failed annuloplasty ring; the transcatheter artificial biological valve-in-ring (20) is delivered to the transcatheter valve-in-ring anchoring stent (10) for release, the stent of the transcatheter artificial biological valve-in-ring (20) deforms and expands to the f

Abstract: Methods and systems that determine levels of leukemia or lymphoma are described. A model using biomarkers such as nuclear size, nuclear intensity, cellular density, and cell-to-nearest-neighbor distance may distinguish samples with chronic lymphocytic leukemia (CLL) progression, accelerated CLL (aCLL), and transformation to diffuse large B-cell lymphoma (Richter transformation; RT). Additionally, using a heat value based on nuclear size and nuclear intensity allowed for visualization or identification of proliferation centers (PCs) and also could be used to diagnose tissue samples from subjects with CLL. Some embodiments use unsupervised clustering to divide lymphoid cells into different cell types, and feature values of these cell types can be used to classify disorders. Methods and systems may accurately and efficiently diagnose levels of a disorder. Diagnosis may be performed with less biological sample (e.g., from a core-needle biopsy), resulting in a more rapid and minimally invasive biopsy.

Abstract: The split type precisely-anchorable transcatheter tricuspid valve system comprises a split transcatheter tricuspid valve anchoring stent (10) and a transcatheter artificial biological tricuspid valve (20), wherein the shape and structure of the transcatheter tricuspid valve anchoring stent (10) are matched with the tricuspid valve real structure after the patient's image data is subjected to three-dimensional reconstruction, the transcatheter tricuspid valve anchoring stent (10) is firstly delivered to the tricuspid valve site of the patient to be released, deformed and personalized and precise alignment with a supravalvular (40) and subvalvular (50) tissue of the patient's tricuspid valve site; the transcatheter artificial biological tricuspid valve (20) is delivered into the transcatheter tricuspid valve anchoring stent (10) to be released, and the transcatheter artificial biological tricuspid valve (20) is released and deformed and expanded to a functional state, the transcatheter tricuspid valve anchoring

Abstract: A split type precisely-anchorable transcatheter aortic valve system comprises a split transcatheter aortic valve anchoring stent (10) and a transcatheter artificial biological aortic valve (20), wherein the shape and structure of the transcatheter aortic valve anchoring stent (10) are matched with the real structure of the aortic valve after the patient's image data is subjected to three-dimensional reconstruction, the transcatheter aortic valve anchoring stent (10) is delivered to the aortic valve position of the patient to be released, deformed and combined with the aortic valve leaflet tissue and the subvalvular tissue of the patient; the transcatheter artificial biological aortic valve (20) is delivered into the transcatheter aortic valve anchoring stent (10) to be released, the valve stent is deformed to expand the valve to the functional state, the transcatheter aortic valve anchoring stent (10) is deformed again and combined with the expanded transcatheter artificial biological aortic valve (20), and m

Abstract: A split type precisely-anchorable transcatheter mitral valve system comprises a split transcatheter mitral valve anchoring stent (10) and a transcatheter artificial biological mitral valve (20), wherein the shape and structure of the transcatheter mitral valve anchoring stent (10) are matched with the mitral valve real structure after the patient image data is subjected to three-dimensional reconstruction, the transcatheter mitral valve anchoring stent (10) is firstly delivered to the mitral valve position of the patient to be released and deformed, and the transcatheter artificial biological mitral valve (20) is in personalized precise alignment and coaptation with tissues on the mitral valve position of the patient and under the petals; the transcatheter artificial biological mitral valve (20) is delivered into the transcatheter mitral valve anchoring stent (10) to be released, the transcatheter artificial biological mitral valve (20) is released and deformed and expanded to a functional state, the transcat

Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.

Abstract: The present disclosure belongs to the technical field of antimicrobial peptide (AMP) production, and relates to a medium for breeding a Hermetia illucens larva that produces a highly active antimicrobial peptide (AMP), a breeding method, and an extraction method of an AMP. The present disclosure provides a medium for breeding a Hermetia illucens larva that produces a highly active AMP, including wheat bran, where the medium has a moisture content of 65% to 70%. In the present disclosure, the medium can realize the rapid and effective production of the highly active AMP by the Hermetia illucens larva.

Abstract: An interleaving driving method of light emitting diode array comprises: receiving image signal; converting the image signal into gray scale signals, the gray scale signals correspond to the plurality of light emitting channels, respectively, to execute multiple steps. The multiple steps include: generating a high gray scale data group and a low gray scale data group; when there is data in the high gray scale data group, drive the light emitting diode channel corresponding to the target gray scale signal during a first turn on time interval; when there is data in the low gray scale data group, drive the light emitting diode channel corresponding to the target gray scale signal during a second turn on time interval which does not overlap the first turn on time interval and a first gray scale signal and a second gray scale signal of the gray scale signals does not overlap each other.

Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

Abstract: Methods, systems, and media for presenting search results are provided. In accordance with some embodiments, the method comprises: receiving text corresponding to a search query; determining whether a content rating score associated with the search query is below a predetermined threshold, wherein the score is calculated by: identifying a first plurality of search results retrieved using the search query, wherein each search result is associated with one of a plurality of content ratings classes; and calculating the content rating score that is a proportion of search results associated with at least one of the content ratings classes among the first plurality of search results; in response to determining that the content rating score is below the predetermined threshold, identifying a second plurality of search results to be presented based on the search query; and causing the second plurality of search results to be presented.

Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.

Abstract: Methods, systems, and media for presenting search results are provided. In accordance with some embodiments, the method comprises: receiving text corresponding to a search query; determining whether a content rating score associated with the search query is below a predetermined threshold, wherein the score is calculated by: identifying a first plurality of search results retrieved using the search query, wherein each search result is associated with one of a plurality of content ratings classes; and calculating the content rating score that is a proportion of search results associated with at least one of the content ratings classes among the first plurality of search results; in response to determining that the content rating score is below the predetermined threshold, identifying a second plurality of search results to be presented based on the search query; and causing the second plurality of search results to be presented.

Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

Abstract: A display system includes a light emitting array and a driving device. The light emitting array includes multiple scan lines, multiple drive lines and multiple light emitting elements. The driving device includes a controller, a charge balance line and a charge sharing circuit. The controller generates a control output. The charge sharing circuit is coupled to the drive lines, the charge balance line and the controller, and receives the control output from the controller. With respect to each of the drive lines, the charge sharing circuit is operable, based on the control output, to establish or not establish an electrical connection between the drive line and the charge balance line.

Abstract: An automatic measurement system for Sludge settling Velocity comprises a sampling and shooting module, a data service module, data processing module, and a measurement and analysis module. The sampling and shooting module is configured to collect samples and to obtain a test images of samples. The data processing module is configured to collect and store process data. The measurement and analysis module is configured to obtain the sedimentation ratios of samples according to test images. The sludge activity is analyzed according to the sedimentation ratios. When the sludge activity is abnormal, the process data are obtained from data processing module, and the process analysis data are obtained according to the data and the sludge activity analysis results. The automatic measurement system can avoid errors caused by manual measurement and improve accuracy and efficiency of detection and can avoid the problems of untimely detection.

Abstract: Various embodiments disclose an electronic circuit for an electrochemical gas sensor. The electronic circuit comprises a first switching element electrically coupled to a reference terminal of the electrochemical gas sensor and a ground voltage terminal. Further, the electronic circuit comprises a second switching element electrically coupled to a sensing terminal of the electrochemical gas sensor and the ground voltage terminal. In an instance in which the electrochemical gas sensor is powered OFF, the first switching element and the second switching element are configured to electrically couple the reference terminal and the sensing terminal to the ground voltage terminal such that current generated when the sensing electrode and the target gas react while the electrochemical gas sensor is powered OFF flows to the ground voltage terminal and the potential of the reference terminal and the sensing terminal remain the equal.